Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Crisugabalin SCHEMBL28524348 | 1.00 | POLB (0.35) | POLBUSP2ALDH1A1LMNACYP1A2 | |
| Crisugabalin SCHEMBL19982295 | 1.00 | POLB (0.35) | POLBUSP2ALDH1A1LMNACYP1A2 | |
| Crisugabalin SCHEMBL21144566 | 1.00 | POLB (0.35) | POLBUSP2ALDH1A1LMNACYP1A2 | |
| Crisugabalin SCHEMBL24631233 | 1.00 | POLB (0.35) | POLBUSP2ALDH1A1LMNACYP1A2 | |
| Crisugabalin SCHEMBL21144567 | 1.00 | POLB (0.35) | POLBUSP2ALDH1A1LMNACYP1A2 | |
| Crisugabalin SCHEMBL23080519 | 1.00 | POLB (0.35) | POLBUSP2ALDH1A1LMNACYP1A2 | |
| Crisugabalin SCHEMBL23071142 | 1.00 | POLB (0.35) | POLBUSP2ALDH1A1LMNACYP1A2 | |
| Crisugabalin SCHEMBL23080592 | 1.00 | POLB (0.35) | POLBUSP2ALDH1A1LMNACYP1A2 | |
| Crisugabalin SCHEMBL21621701 | 1.00 | POLB (0.35) | POLBUSP2ALDH1A1LMNACYP1A2 | |
| Crisugabalin SCHEMBL19982362 | 1.00 | POLB (0.35) | POLBUSP2ALDH1A1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230320989-A1 | SUSTAINED-RELEASE PHARMACEUTICAL FORMULATION OF FUSED TRICYCLIC ?-AMINO ACID DERIVATIVE AND PREPARATION METHOD THEREFOR | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230320989-A1 | SUSTAINED-RELEASE PHARMACEUTICAL FORMULATION OF FUSED TRICYCLIC ?-AMINO ACID DERIVATIVE AND PREPARATION METHOD THEREFOR | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| CN-112384493-B | Process for preparing fused tricyclic gamma-amino acid derivatives and intermediates | 四川海思科制药有限公司 | 2023-06-06 | — | — | CN | disclosed |
| EP-3527552-B1 | FUSED TRICYCLIC GAMMA-AMINO ACID DERIVATIVE, PREPARATION METHOD THEREFORE, AND MEDICAL USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO LTD (CN) | 2022-11-30 | — | — | EP | disclosed |
| US-20210186909-A1 | COMPOSITION OF FUSED TRICYCLIC GAMMA-AMINO ACID DERIVATIVES AND THE PREPARATION THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2021-06-24 | — | — | US | disclosed |
| EP-3822252-A1 | COMPOSITION OF FUSED TRICYCLIC GAMMA-AMINO ACID DERIVATIVE AND PREPARATION THEREFOR | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2021-05-19 | — | — | EP | disclosed |
| WO-2020155953-A1 | FUSED TRICYCLIC DEUTERATED DERIVATIVE, COMPOSITION AND USE THEREOF | 四川海思科制药有限公司 | 2020-08-06 | — | — | WO | disclosed |
| US-10654794-B2 | Fused tricyclic Γ-amino acid derivative, preparation method therefor, and medical use thereof | SICHUAN HAISO PHARMACEUTICAL CO., LTD. (CN) | 2020-05-19 | — | — | US | disclosed |
| WO-2020011257-A1 | COMPOSITION OF FUSED TRICYCLIC γ-AMINO ACID DERIVATIVE AND PREPARATION THEREFOR | 四川海思科制药有限公司 | 2020-01-16 | — | — | WO | disclosed |
| EP-3527552-A1 | FUSED TRICYCLIC -AMINO ACID DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2019-08-21 | — | — | EP | disclosed |
| US-20190218172-A1 | FUSED TRICYCLIC GAMMA-AMINO ACID DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | SICHUAN HAISO PHARMACEUTICAL CO., LTD. (CN) | 2019-07-18 | — | — | US | disclosed |
| WO-2018050046-A1 | FUSED TRICYCLIC Γ-AMINO ACID DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 四川海思科制药有限公司 | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230320989-A1 | SUSTAINED-RELEASE PHARMACEUTICAL FORMULATION OF FUSED TRICYCLIC ?-AMINO ACID DERIVATIVE AND PREPARATION METHOD THEREFOR | SLC38A7, SLC7A1, SLC6A11 | POLB 4316/4885USP2 2662/4885ALDH1A1 1227/4885 |
| US-20210186909-A1 | COMPOSITION OF FUSED TRICYCLIC GAMMA-AMINO ACID DERIVATIVES AND THE PREPARATION THEREOF | AADAT, DDC, AAAS | POLB 346/4885USP2 3745/4885ALDH1A1 1534/4885 |
| US-20190218172-A1 | FUSED TRICYCLIC GAMMA-AMINO ACID DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | SLC38A7, BCAT2, SLC6A11 | POLB 2881/4885USP2 4054/4885ALDH1A1 564/4885 |
| US-10654794-B2 | Fused tricyclic Γ-amino acid derivative, preparation method therefor, and medical use thereof | SLC38A7, BCAT2, BCAT1 | POLB 3130/4885USP2 4150/4885ALDH1A1 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.